Desloratadine
| Evidence Level: L1 | Predicted Indications: 6 |
Table of Contents
Desloratadine: From Allergic Rhinitis/Chronic Urticaria to Cold Urticaria
One-Sentence Summary
Desloratadine is a second-generation H1-antihistamine established for allergic rhinitis and chronic urticaria. The TxGNN model predicts it may be effective for Cold Urticaria (acquired cold urticaria, ACU), with 3 clinical trials and 7 publications currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Allergic rhinitis / chronic urticaria (established antihistamine class use; no UK marketing authorisation record found in this evidence pack) |
| Predicted New Indication | Cold Urticaria |
| TxGNN Prediction Score | 99.94% |
| Evidence Level | L1 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed mechanism-of-action documentation for desloratadine is not available in this evidence pack. Based on known pharmacology, desloratadine is a highly selective peripheral H1-receptor antagonist within the second-generation antihistamine class, and its efficacy in allergic rhinitis and chronic urticaria is well established.
The wheal-and-flare response seen in cold urticaria is driven by mast cell degranulation and histamine release, which activates H1 receptors on cutaneous sensory nerves. Because desloratadine directly blocks this same H1 pathway, its established mechanism maps closely onto the pathophysiology of cold urticaria, which is itself a physical subtype of urticaria.
This mechanistic overlap is reinforced by clinical guidance: antihistamines are already recommended as first-line therapy for cold-induced urticaria under EAACI/GA²LEN guidelines, which supports the biological plausibility of the TxGNN prediction rather than requiring an entirely novel mechanistic rationale.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT01444196 | Phase 4 | Completed | 30 | Multi-centre, double-blind, dose-escalating study comparing desloratadine 5 mg/10 mg/20 mg to identify the dose sufficient to inhibit cold urticaria symptoms |
| NCT00600847 | Phase 4 | Completed | 33 | Randomised, double-blind, placebo-controlled crossover study comparing 5 mg vs 20 mg desloratadine on experimentally induced cold urticaria lesions; higher dosing was more effective than standard dose or placebo |
| NCT01940393 | Phase 4 | Completed | 150 | Evaluated the inhibitory effect of five antihistamines (desloratadine among them) on urticaria symptoms in a tropical Latin American population |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 19201016 | 2009 | RCT | J Allergy Clin Immunol | Randomised, placebo-controlled crossover trial showing high-dose desloratadine reduced wheal volume and improved cold provocation thresholds versus standard dose |
| 22242678 | 2012 | RCT | Br J Dermatol | Randomised controlled trial establishing critical temperature threshold measurement to assess H1-antihistamine dose escalation response in cold urticaria |
| 14754651 | 2004 | RCT | J Dermatolog Treat | 5 mg desloratadine for 4 days significantly inhibited ice-cube-induced wheal responses in 12 patients with cold urticaria |
| 15516152 | 2004 | Review | Drugs | Review of chronic urticaria aetiology, management, and current/future treatment options |
| 19032340 | 2008 | Review | Allergy | Review of ebastine (another second-generation antihistamine) in allergic rhinitis and chronic idiopathic urticaria, providing class-level context |
| 38025339 | 2023 | Case Report | Qatar Med J | Case report of cold-induced urticaria following black ant bite anaphylaxis |
| 29698807 | 2018 | Case Report | J Allergy Clin Immunol Pract | Description of food-dependent cold urticaria as a novel physical urticaria variant |
UK Market Information
No UK marketing authorisation records were identified for desloratadine in this evidence pack. Market status is recorded as Not Marketed, with 0 licences on file. Prescribers should verify current MHRA product licensing directly via the MHRA products register and BNF before considering any prescribing pathway.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Three completed Phase 4 RCTs and multiple supporting publications (including two dedicated dose-response RCTs) directly evaluate desloratadine in cold urticaria, and the mechanistic rationale is well supported by established antihistamine pharmacology. However, no UK marketing authorisation or MHRA-approved SmPC safety data are currently available for this drug.
To proceed, the following is needed:
- MHRA-approved SmPC (warnings, contraindications, drug interactions) — currently a blocking data gap
- Confirmed mechanism-of-action documentation from DrugBank or equivalent source
- Confirmation of current UK licensing/import pathway, since no marketing authorisation is on record
- A formal off-label prescribing risk assessment given the absence of a UK licence for this indication
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.